2026 Q1 -tulosraportti
Vain PDF
13 päivää sitten
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 929 | - | - | ||
| 2 702 | - | - | ||
| 20 | - | - | ||
| 2 678 | - | - | ||
| 2 678 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 63 516 | 63 516 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 63 516 | 63 516 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenStock status Canngo: in stock There are 3 pharmacies that sell Astrum (It's only today that I found out the number of pharmacies) Now that the price has been asked about, this topic is also different from in Denmark. In Denmark, prescription medicine has the same price everywhere. But that's not the case in Germany. As I have stated several times, you need a prescription to get access to the price from most providers. but the few I can see are 3.33€ to 4.52€ (I read the following on Google) But we can indirectly find out if Stenocare earns more or less money per bottle sold. It is such in Germany that the price of a product that is prescription-only does not necessarily cost the same everywhere in Germany; it is up to the pharmacies to set the price of the products they sell. I have put it in bullet points and simplified it, because like everything else in Germany, it is complicated: It typically happens in such a way. - if few people buy the medical item, the item will be an order item and the price will be at the lowest level. - If enough people buy the item for it to be in stock, but no more than that, the price will be low, and slightly higher than if it is an order item. - If even more people buy the item, and there is a certain flow in the warehouse, the price will be slightly higher - If the item becomes very popular, the price will also be screwed up even higher. What can we use this for? Since Stenocare only gets money when the prescription is redeemed, we can calculate that in areas where there is a small flow, the price of Astrum10-10 is cheapest, and here Stenocare will get less money per. sold bottle. Where the flow is larger, we can expect Stenocare to get more money per. sold bottle there. As I remember it, Stenocare gets percentages and not a fixed price per. sold unit. Therefore, it is a greater advantage for Stenocare that Stenocare is settled with the end-users, and not with the distributor. (besides it being more accurate) Because the German system is structured in this way, Stenocare will never get into trouble in the German system if the price becomes very high. An example could be the much-discussed obesity preparations, where Novo was blamed for screwing up the price too high (I am describing the situation and not the product) Stenocare will get off scot-free because it is the pharmacies that raise the price, which they can do because it is the insurance companies that pay. Not the end-users, or the doctors, nor the public health insurance system. Because it is the insurance companies that pay, doctors are more willing to prescribe Astrum10-10 I should also mention that Astrum10-10 resembles the medicine doctors are trained in. which also contributes to doctors feeling comfortable prescribing Astrum10-10- ·2 päivää sittenStock status I can confirm that it's going the right way, forward, steadily. New Green Medical - in stock Is nationwide - Can be obtained at two pharmacies, one in Berlin and the other in Düsseldorf CannabisApo24 - in stock·1 päivä sittenThanks K1000. You are right, it's per ml. I cannot find other prices, because most state the price when you have provided your prescription number. I haven't looked much into the price, because as I wrote, the pharmacy determines their own prices. As I have written earlier, the market is completely opaque, and one really has to go into detail to get a reasonable overview and to avoid duplicates. In my search to find pharmacies that sell Astrum10-10, I have found that a company can own the entire distribution chain. E.g., a pharmacy can be the main owner, and then that pharmacy can have 2 subsidiaries. One is the distributor and the other is what they call telemedicine; these are the ones who issue prescriptions online. For your information, there is still a big debate in Germany about whether telemedicine can continue.·1 päivä sittenYou yourself write that it's completely opaque, while at the same time you believe you can get an overview of an entire market by observing what's on the shelves in a couple of pharmacies, and that in a huge country like Germany. It's a bit like imagining you can get a precise picture of what the total bread market looks like by observing a couple of shelves in the local Netto. It's incomprehensible to me that you yourself cannot see that your method is so flawed that it has no value.
·2 päivää sittenI'll stick with it for a while longer as long as I believe in the product.
·1 päivä sittenAgreed. However, I give them the 2026 financial year to show that there is now progress. Should I keep them, they must not be extraordinary in 2027.
·2 päivää sittenHave bought x-number when They came on the market (listed on the stock exchange), saw it as a sensible business for the investment, as the market is there. The company has not been able to live up to that. Someone has made money.! All other companies within the industry can make money, generate value. So should I sell and take a big loss, or bet on the adults being able to achieve growth in the future .?·2 päivää sittenIf you sell and buy again, you get a deduction on the loss, which is deducted from the profit. But if it's because you're in doubt whether you should stay in the stock, then you can read below about the considerations I have about this stock. You've been involved longer than I have, and therefore you have a backpack full of disappointments and broken promises, (I've read that) I only got into Stenocare when they had completely phased out production. I can only say that they have put extra oomph into the promotion of Astrum10-10 oil after the oil has received all the advantages one can get in Germany if the medicine is to become a sales success there. The four advantages: It is approved by the two largest insurance companies. It has 100 % reimbursement It has received fast track status and last but not least, that the oil resembles the medicine that doctors are trained to use. The four advantages remove all doctors' fear of prescribing Astrum10-10, so these advantages are the reason why Stenocare's management and analysts agree that Astrum 10-10 will become very valuable for Stenocare. Since I am annoyed that Stenocare's management has decided that they want to own the narrative, and thus will not answer questions from us shareholders, I have found an alternative way for us to follow whether Weeco gets doctors to prescribe more prescriptions or not, which I do by following approx 15 online pharmacies in Germany, and seeing if more or fewer have the oil in stock. I write about this on Nordnet social. The risk with this stock will be, or the fly in the ointment will be, that Stenocare's target 0,3 does not deliver, but so far they are following the plan. this is the latest analysis I could find. https://analystgroup.se/kommentarer/comment-on-stenocares-q4-report-2025/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
13 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenStock status Canngo: in stock There are 3 pharmacies that sell Astrum (It's only today that I found out the number of pharmacies) Now that the price has been asked about, this topic is also different from in Denmark. In Denmark, prescription medicine has the same price everywhere. But that's not the case in Germany. As I have stated several times, you need a prescription to get access to the price from most providers. but the few I can see are 3.33€ to 4.52€ (I read the following on Google) But we can indirectly find out if Stenocare earns more or less money per bottle sold. It is such in Germany that the price of a product that is prescription-only does not necessarily cost the same everywhere in Germany; it is up to the pharmacies to set the price of the products they sell. I have put it in bullet points and simplified it, because like everything else in Germany, it is complicated: It typically happens in such a way. - if few people buy the medical item, the item will be an order item and the price will be at the lowest level. - If enough people buy the item for it to be in stock, but no more than that, the price will be low, and slightly higher than if it is an order item. - If even more people buy the item, and there is a certain flow in the warehouse, the price will be slightly higher - If the item becomes very popular, the price will also be screwed up even higher. What can we use this for? Since Stenocare only gets money when the prescription is redeemed, we can calculate that in areas where there is a small flow, the price of Astrum10-10 is cheapest, and here Stenocare will get less money per. sold bottle. Where the flow is larger, we can expect Stenocare to get more money per. sold bottle there. As I remember it, Stenocare gets percentages and not a fixed price per. sold unit. Therefore, it is a greater advantage for Stenocare that Stenocare is settled with the end-users, and not with the distributor. (besides it being more accurate) Because the German system is structured in this way, Stenocare will never get into trouble in the German system if the price becomes very high. An example could be the much-discussed obesity preparations, where Novo was blamed for screwing up the price too high (I am describing the situation and not the product) Stenocare will get off scot-free because it is the pharmacies that raise the price, which they can do because it is the insurance companies that pay. Not the end-users, or the doctors, nor the public health insurance system. Because it is the insurance companies that pay, doctors are more willing to prescribe Astrum10-10 I should also mention that Astrum10-10 resembles the medicine doctors are trained in. which also contributes to doctors feeling comfortable prescribing Astrum10-10
- ·2 päivää sittenStock status I can confirm that it's going the right way, forward, steadily. New Green Medical - in stock Is nationwide - Can be obtained at two pharmacies, one in Berlin and the other in Düsseldorf CannabisApo24 - in stock·1 päivä sittenThanks K1000. You are right, it's per ml. I cannot find other prices, because most state the price when you have provided your prescription number. I haven't looked much into the price, because as I wrote, the pharmacy determines their own prices. As I have written earlier, the market is completely opaque, and one really has to go into detail to get a reasonable overview and to avoid duplicates. In my search to find pharmacies that sell Astrum10-10, I have found that a company can own the entire distribution chain. E.g., a pharmacy can be the main owner, and then that pharmacy can have 2 subsidiaries. One is the distributor and the other is what they call telemedicine; these are the ones who issue prescriptions online. For your information, there is still a big debate in Germany about whether telemedicine can continue.·1 päivä sittenYou yourself write that it's completely opaque, while at the same time you believe you can get an overview of an entire market by observing what's on the shelves in a couple of pharmacies, and that in a huge country like Germany. It's a bit like imagining you can get a precise picture of what the total bread market looks like by observing a couple of shelves in the local Netto. It's incomprehensible to me that you yourself cannot see that your method is so flawed that it has no value.
- ·2 päivää sittenI'll stick with it for a while longer as long as I believe in the product.·1 päivä sittenAgreed. However, I give them the 2026 financial year to show that there is now progress. Should I keep them, they must not be extraordinary in 2027.
- ·2 päivää sittenHave bought x-number when They came on the market (listed on the stock exchange), saw it as a sensible business for the investment, as the market is there. The company has not been able to live up to that. Someone has made money.! All other companies within the industry can make money, generate value. So should I sell and take a big loss, or bet on the adults being able to achieve growth in the future .?·2 päivää sittenIf you sell and buy again, you get a deduction on the loss, which is deducted from the profit. But if it's because you're in doubt whether you should stay in the stock, then you can read below about the considerations I have about this stock. You've been involved longer than I have, and therefore you have a backpack full of disappointments and broken promises, (I've read that) I only got into Stenocare when they had completely phased out production. I can only say that they have put extra oomph into the promotion of Astrum10-10 oil after the oil has received all the advantages one can get in Germany if the medicine is to become a sales success there. The four advantages: It is approved by the two largest insurance companies. It has 100 % reimbursement It has received fast track status and last but not least, that the oil resembles the medicine that doctors are trained to use. The four advantages remove all doctors' fear of prescribing Astrum10-10, so these advantages are the reason why Stenocare's management and analysts agree that Astrum 10-10 will become very valuable for Stenocare. Since I am annoyed that Stenocare's management has decided that they want to own the narrative, and thus will not answer questions from us shareholders, I have found an alternative way for us to follow whether Weeco gets doctors to prescribe more prescriptions or not, which I do by following approx 15 online pharmacies in Germany, and seeing if more or fewer have the oil in stock. I write about this on Nordnet social. The risk with this stock will be, or the fly in the ointment will be, that Stenocare's target 0,3 does not deliver, but so far they are following the plan. this is the latest analysis I could find. https://analystgroup.se/kommentarer/comment-on-stenocares-q4-report-2025/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 929 | - | - | ||
| 2 702 | - | - | ||
| 20 | - | - | ||
| 2 678 | - | - | ||
| 2 678 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 63 516 | 63 516 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 63 516 | 63 516 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
13 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenStock status Canngo: in stock There are 3 pharmacies that sell Astrum (It's only today that I found out the number of pharmacies) Now that the price has been asked about, this topic is also different from in Denmark. In Denmark, prescription medicine has the same price everywhere. But that's not the case in Germany. As I have stated several times, you need a prescription to get access to the price from most providers. but the few I can see are 3.33€ to 4.52€ (I read the following on Google) But we can indirectly find out if Stenocare earns more or less money per bottle sold. It is such in Germany that the price of a product that is prescription-only does not necessarily cost the same everywhere in Germany; it is up to the pharmacies to set the price of the products they sell. I have put it in bullet points and simplified it, because like everything else in Germany, it is complicated: It typically happens in such a way. - if few people buy the medical item, the item will be an order item and the price will be at the lowest level. - If enough people buy the item for it to be in stock, but no more than that, the price will be low, and slightly higher than if it is an order item. - If even more people buy the item, and there is a certain flow in the warehouse, the price will be slightly higher - If the item becomes very popular, the price will also be screwed up even higher. What can we use this for? Since Stenocare only gets money when the prescription is redeemed, we can calculate that in areas where there is a small flow, the price of Astrum10-10 is cheapest, and here Stenocare will get less money per. sold bottle. Where the flow is larger, we can expect Stenocare to get more money per. sold bottle there. As I remember it, Stenocare gets percentages and not a fixed price per. sold unit. Therefore, it is a greater advantage for Stenocare that Stenocare is settled with the end-users, and not with the distributor. (besides it being more accurate) Because the German system is structured in this way, Stenocare will never get into trouble in the German system if the price becomes very high. An example could be the much-discussed obesity preparations, where Novo was blamed for screwing up the price too high (I am describing the situation and not the product) Stenocare will get off scot-free because it is the pharmacies that raise the price, which they can do because it is the insurance companies that pay. Not the end-users, or the doctors, nor the public health insurance system. Because it is the insurance companies that pay, doctors are more willing to prescribe Astrum10-10 I should also mention that Astrum10-10 resembles the medicine doctors are trained in. which also contributes to doctors feeling comfortable prescribing Astrum10-10
- ·2 päivää sittenStock status I can confirm that it's going the right way, forward, steadily. New Green Medical - in stock Is nationwide - Can be obtained at two pharmacies, one in Berlin and the other in Düsseldorf CannabisApo24 - in stock·1 päivä sittenThanks K1000. You are right, it's per ml. I cannot find other prices, because most state the price when you have provided your prescription number. I haven't looked much into the price, because as I wrote, the pharmacy determines their own prices. As I have written earlier, the market is completely opaque, and one really has to go into detail to get a reasonable overview and to avoid duplicates. In my search to find pharmacies that sell Astrum10-10, I have found that a company can own the entire distribution chain. E.g., a pharmacy can be the main owner, and then that pharmacy can have 2 subsidiaries. One is the distributor and the other is what they call telemedicine; these are the ones who issue prescriptions online. For your information, there is still a big debate in Germany about whether telemedicine can continue.·1 päivä sittenYou yourself write that it's completely opaque, while at the same time you believe you can get an overview of an entire market by observing what's on the shelves in a couple of pharmacies, and that in a huge country like Germany. It's a bit like imagining you can get a precise picture of what the total bread market looks like by observing a couple of shelves in the local Netto. It's incomprehensible to me that you yourself cannot see that your method is so flawed that it has no value.
- ·2 päivää sittenI'll stick with it for a while longer as long as I believe in the product.·1 päivä sittenAgreed. However, I give them the 2026 financial year to show that there is now progress. Should I keep them, they must not be extraordinary in 2027.
- ·2 päivää sittenHave bought x-number when They came on the market (listed on the stock exchange), saw it as a sensible business for the investment, as the market is there. The company has not been able to live up to that. Someone has made money.! All other companies within the industry can make money, generate value. So should I sell and take a big loss, or bet on the adults being able to achieve growth in the future .?·2 päivää sittenIf you sell and buy again, you get a deduction on the loss, which is deducted from the profit. But if it's because you're in doubt whether you should stay in the stock, then you can read below about the considerations I have about this stock. You've been involved longer than I have, and therefore you have a backpack full of disappointments and broken promises, (I've read that) I only got into Stenocare when they had completely phased out production. I can only say that they have put extra oomph into the promotion of Astrum10-10 oil after the oil has received all the advantages one can get in Germany if the medicine is to become a sales success there. The four advantages: It is approved by the two largest insurance companies. It has 100 % reimbursement It has received fast track status and last but not least, that the oil resembles the medicine that doctors are trained to use. The four advantages remove all doctors' fear of prescribing Astrum10-10, so these advantages are the reason why Stenocare's management and analysts agree that Astrum 10-10 will become very valuable for Stenocare. Since I am annoyed that Stenocare's management has decided that they want to own the narrative, and thus will not answer questions from us shareholders, I have found an alternative way for us to follow whether Weeco gets doctors to prescribe more prescriptions or not, which I do by following approx 15 online pharmacies in Germany, and seeing if more or fewer have the oil in stock. I write about this on Nordnet social. The risk with this stock will be, or the fly in the ointment will be, that Stenocare's target 0,3 does not deliver, but so far they are following the plan. this is the latest analysis I could find. https://analystgroup.se/kommentarer/comment-on-stenocares-q4-report-2025/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 8 929 | - | - | ||
| 2 702 | - | - | ||
| 20 | - | - | ||
| 2 678 | - | - | ||
| 2 678 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 63 516 | 63 516 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 63 516 | 63 516 | 0 | 0 |